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Dismantling Limb-GirdleMuscular Dystrophy
The Role ofWhole-Exome Sequencing
Pushpa Narayanaswami, MBBS, DM
Muscular dystrophy encompasses a diverse group of geneti-
cally determined muscle disorders. The first clinical descrip-
tion of the disorder is attributed to Giovanni Semmola, who,
in 1829, described 2 boys affected by a disorder with promi-
nent muscular hypertrophy.1
Between1850and1868,Aran,
Meryon, and Duchenne de-
scribed a progressive atro-
phy of voluntarymuscles, ultimately termed pseudohypertro-
phic muscular paralysis of children by Duchenne.1,2 Other
descriptions followed: familial atrophy of the pelvic girdle
muscles (Leyden in 1876), scapulohumeral muscular atrophy
(Erb in 1884), andmyopathy with facial weakness (Landouzy
and Dejerine in 1884).1 The term limb-girdle muscular dystro-
phy (LGMD), suggested by Stevenson in 1953,3 and further de-
tailed byWalton and Nattrass in a seminal article,2 refers to a
group of muscular dystrophies with onset of weakness in the
shoulder or pelvic girdles.4 The variable clinical course of this
disorder was recognized even in these early descriptions.2,3
Traditionalneurologyemphasizestheroleofthehistoryand
clinical examination in arriving at a diagnosis. The clinical ap-
proach to patients with suspected myopathy includes obtain-
ing a history of symptom evolution, comprehensive pedigree
analysis, evaluation of the distribution ofweakness, and iden-
tificationofextramuscularmanifestations.Neuromuscularneu-
rologistsoftenusea“patternrecognition”approach,whichclas-
sifiesmuscleweakness intospecific schema: limbgirdle,distal,
humeroperoneal, etc. There is value to this clinical approach,
which allows one to narrow the diagnosis down to a few con-
ditions, or even a single condition, to inform subsequent con-
firmatory testing. A young boy with onset of weakness in the
first decade, calf hypertrophy, Gowers maneuver, and a simi-
larly affected maternal uncle is likely to have Duchenne mus-
cular dystrophy. For a youngadultwithmyotonia, ptosis, tem-
poralis atrophy, distal limb weakness, and a family history
suggesting autosomal dominant inheritance, clinical suspi-
cionofmyotonicdystrophy leads to confirmatorygenetic test-
ing. However, genetic heterogeneity (ie, the existence of simi-
lar phenotypes due to different genetic mutations) limits the
diagnostic capacity of phenotypic classifications.
In1987, thediscoveryofthegeneticdefectandproteinprod-
uct, dystrophin, in Duchennemuscular dystrophy revolution-
ized the approach tomuscular dystrophies.5 Aneraofmolecu-
lar diagnoses was born. As the search for genetic causes for
neuromuscular disorders continued, it became apparent that
LGMD was not a single disease but likely represented several
disorders unified by their phenotype. After reports of autoso-
mal recessive LGMD from the 1950s on, Fardeau and col-
leagues, in1989,describedanautosomal recessiveLGMDonthe
French island of Réunion; in 1991, this disorder was found to
link to chromosome 15q, and in 1995, it was identified as
calpainopathy.6 In 1986,a reportofautosomaldominantLGMD
established thegeneticheterogeneityof this syndrome.7Asub-
sequent family with autosomal dominant LGMD reported in
1988was found tohave a type of LGMD that linked to chromo-
some5q in 1992, and in2000, this familywas identifiedashav-
ing amutation in themyotilin gene.8Agenetic classificationof
LGMDs was proposed in 1995, based on the inheritance pat-
tern: Type 1 LGMDs are autosomal dominant, and type 2LMG-
MDsare autosomal recessive.A letter defining theorder ofdis-
covery of the chromosomal locus is appended to the numeric
designation.9 The list of LGMDs with known genetic loci con-
tinuestogrowrapidly(8autosomaldominantLGMDs[LGMD1A-
1H) and 23 autosomal recessive LGMDs [LGMD2A-2W]).10
A definitive diagnosis of the type of LGMD is important;
it avoids repeated testing or empirical, potentially toxic treat-
ments for acquired causes such as inflammatory myopathy;
provides patients with a sense of closure; assists genetic
counseling; and aids the identification and treatment of
complications.11 In the future, knowledgeof theunderlyingge-
neticmutationwill benecessary forenrollment inclinical trials
of targeted therapies. However, the genetic heterogeneity of
the LGMDphenotypemakes establishing a definitive diagno-
sis challenging. The approach to diagnosis is complex and in-
cludes evaluation of the inheritance pattern and identifica-
tion of specific clinical features that direct further testing.11
Conventional genetic testing formendeliandisorders such
as LGMD involve genome-wide linkage to identifymutations
that cosegregate within affected individuals, positional clon-
ing, and, finally, targeted candidate gene sequencing.12 In au-
tosomal recessive disorders, autozygosity mapping, which
identifies regions of the genome that are homozygous in af-
fected individualsbutnot inunaffected familymembers, is fol-
lowed by gene sequencing to identify the causal mutation.13
These techniques assume the availability of several affected
familymembersandareof limitedutilitywhenonlya fewcases
are available or in sporadic cases owing to de novo muta-
tions. In addition, genetic and phenotypic heterogeneity and
incomplete penetrance limit these approaches.13
TheDNAsequencing techniquedescribedbySanger et al14
was used to sequence the human genome in 2001 (theHuman
GenomeProject).15 In2004,next-generationsequencingmeth-
ods (whichusehigh-throughput,massivelyparallel sequencing
platforms)were introduced,making itpossible tosequencesev-
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eral thousandormore fragmentsofDNAsimultaneously.Next-
generationsequencingplatformscancompletegenomesequenc-
ingwithinafewweeksatafractionofthecostofSangersequenc-
ing. Inaddition towhole-genomesequencing,next-generation
sequencingcanbeusedforwhole-exomesequencing(WES).The
exomeis thesequenceofall exonsofprotein-codinggenes, cov-
ering 1% to 2% of the genome, and contains an estimated 85%
ofthemutationsthatcausemendeliandisorders.16Hence,WES,
or targetedsequencingofall knownexons, isoftensufficient to
identify the genes underlyingmendelian disorders.
In WES, genomic DNA is first extracted and broken down
intoshortsegments.PrimingsequencesofDNAareaddedtothe
ends of these fragments. The fragments are then captured by
mixing themwithprobes thatarecomplementary toknownex-
ons in the genome. The remaining DNA is washed away, leav-
ing the enriched exome sequences for amplification andmas-
siveparallel sequencing.Fluorescentnucleotides incorporated
into strands of DNA during the sequencing process are de-
tected using laser activation. Millions of short sequence reads
aremapped to a reference genome, andvariantswithin the ge-
nome are identified.12,17 These variants are then filtered to ex-
cludenonpathogenicpolymorphisms.The first step is to cross-
reference the variants against publicly available databases of
exomes from unaffected individuals. The remaining varia-
tions are then filtered by themode of inheritance, segregation
within affected familymembers, stratification, etc.17
In this issue of JAMANeurology, Ghaoui and colleagues18
describe the application of WES to evaluate patients whose
LGMD subtype remained undiagnosed after immunohisto-
chemistryofmusclebiopsy specimensand targetedSanger se-
quencing, which provided a diagnosis for 83 of 237 families
(35%).Of the remaining 154 families, 100 individuals from60
families underwent WES. Ghaoui et al18 identified patho-
genicmutations in 27 of 60 families (45%). Importantly, they
studied 45 probands without parental DNA, in whom the di-
agnostic rate ofWESwas a respectable 40%,underscoring the
value of this technique in sporadic cases. Twelve families had
a known LGMD-related gene mutation. Six of these repre-
sentedpreviously reportedmutations; it is unclearwhy these
were missed by candidate gene testing.
More interestingly, 14of60familieshadmutations ingenes
that are not classically associated with an LGMD phenotype
(GTDC2, LAMA2, and ACTA1), congenital myasthenia due to
DOK7mutation,orevenmetabolicmyopathy(PYGMandCPT2).
Asecond lookat thephenotypehelpedconfirmthediagnosis in
severalcases:clinical featuresmissedat initialexamination(con-
tractures,scoliosis, follicularhyperkeratosisandkeloids inBeth-
lemmyopathy, low-setears inSTIM1-relatedmyopathywith tu-
bular aggregates, and fatigability incongenitalmyasthenia), re-
view of muscle biopsy (reduced collagen staining, reduced
proteindetectedon immunohistochemistry andWesternblot,
andabsenceof enzymedetectedonhistochemistry),magnetic
resonance imaging of the limbs for patterns ofmuscle atrophy
ormagnetic resonance imagingof thebrain forwhitematterdis-
ease. In 1 family, anovelheterozygousvariant in theCHD7gene
wasdetected.Theprobandhadproximalupperextremityweak-
nessandscapularwingingwithmildmyopathydetetected inbi-
opsyspecimen.OtherphenotypicfeaturesofCHARGEsyndrome
(coloboma,heartdefect,atresiaofthechoanae,retardedgrowth,
andgenitalabnormalities)werenotpresent,but low-setearsand
magneticresonanceimagingevidenceofhypoplasiaof thesemi-
circular canalswere noted (ear abnormalities).
This study18 supports the utility ofWES for the genetic di-
agnosisofLGMD.However, importantethicalconsiderations in-
clude informed consent and themanagement of clinically im-
portant,unrelatedgenetic informationthatmaybe incidentally
uncovered. Ghaoui et al18 correctly point out the limitations of
WES; incompleteenrichmentor“coverage”of thesequencesof
interest is one limitation.Asaconsequence, a sequencingerror
maybefalsely interpretedasamutation,ora truemutationmay
bemissed.Similarly, slightmisalignmentof thesequencedDNA
to the referencegenomemaycause small base substitutionsor
insertions/deletionstobemissed,orcreatetheimpressionofnew
mutations.17 Because the DNA probes are based on sequences
fromknownexons,mutations inunknownexonswillbemissed.
Pathogenicmutations in noncoding elements, introns, regula-
toryelementssuchaspromotersandenhancers,orsplicesitemu-
tationswill also not be detected.16 Repeat expansions are gen-
erally not detectedwith exome sequencing, andGhaoui et al18
appropriatelyexcludedtype2myotonicdystrophyandtype1fa-
cioscapulohumeral muscular dystrophy prior to WES in their
study.Finally, filteringtechniquesmayerroneouslyomitpatho-
genicmutationsbecausemutationcarrierswhohavenotyetex-
pressedthediseaseowingtoreducedpenetrancemaybepresent
in the control databases.17
Where, then,does theclinical armamentariumof the tradi-
tionalneurologist fit in? Is it timetoreplace thephenotypicclas-
sificationwithagenetic classificationofmusculardystrophies?
ArecentreportoftheNationalAcademyofSciencesrecommends
anew,dynamictaxonomyofhumandiseases incorporatingmo-
lecularbiology,clinicaldata,andenvironmentaldatato improve
health care.19 The influenceof yet-to-bediscoveredepigenetic
factors ondisease expressionmust also be considered. The ge-
neticdiagnosisofmusculardystrophies is rapidlyevolving; the
jury is still out on the optimal diagnostic algorithms and tech-
niques and their clinical and genetic implications. Close atten-
tiontoclinicalexaminationincorporatingnotonlytheneurologic
examination but also a detailed multisystem examination re-
mainsanessential part of thediagnostic algorithminmuscular
dystrophy.Long-termfollow-upwillprovidevaluablephenotype-
genotype correlations formanagement of future patients. It is
not yet time to retire our reflex hammers.
ARTICLE INFORMATION
Author Affiliation:Department of Neurology, Beth
Israel Deaconess Medical Center/Harvard Medical
School, Boston, Massachusetts.
Corresponding Author: Pushpa Narayanaswami,
MBBS, DM, Department of Neurology, Beth Israel
Deaconess Medical Center/Harvard Medical School,
Neurology TCC-8, 330 Brookline Ave, Boston, MA
02215 (pnarayan@bidmc.harvard.edu).
Published Online:October 5, 2015.
doi:10.1001/jamaneurol.2015.2749.
Conflict of Interest Disclosures:None reported.
Additional Contributions: I would like to thank
S. Rutkove, MD, at the Department of Neurology,
Beth Israel Deaconess Medical Center, Boston,
Massachusetts, for reviewing themanuscript and
making suggestions on the content. He did not
receive financial compensation.
Opinion Editorial
1410 JAMANeurology December 2015 Volume 72, Number 12 (Reprinted) jamaneurology.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/neur/934755/ by a Harvard University User  on 05/31/2017
Copyright 2015 American Medical Association. All rights reserved.
REFERENCES
1. Angelini C. Chapter 31: muscular dystrophy.
Handb Clin Neurol. 2010;95:477-488.
2. Walton JN, Nattrass FJ. On the classification,
natural history and treatment of themyopathies.
Brain. 1954;77(2):169-231.
3. Stevenson AC. Muscular dystrophy in Northern
Ireland, I: an account of the condition in fifty-one
families. Ann Eugen. 1953;18(1):50-93; contd.
4. Bushby KM. Diagnostic criteria for the
limb-girdle muscular dystrophies: report of the
ENMC Consortium on Limb-Girdle Dystrophies.
Neuromuscul Disord. 1995;5(1):71-74.
5. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP,
Feener C, Kunkel LM. Complete cloning of the
Duchennemuscular dystrophy (DMD) cDNA and
preliminary genomic organization of the DMD gene
in normal and affected individuals. Cell. 1987;50
(3):509-517.
6. Richard I, Broux O, Allamand V, et al. Mutations
in the proteolytic enzyme calpain 3 cause
limb-girdle muscular dystrophy type 2A. Cell. 1995;
81(1):27-40.
7. Chutkow JG, Heffner RR Jr, Kramer AA,
Edwards JA. Adult-onset autosomal dominant
limb-girdle muscular dystrophy. Ann Neurol. 1986;
20(2):240-248.
8. Hauser MA, Horrigan SK, Salmikangas P, et al.
Myotilin is mutated in limb girdle muscular
dystrophy 1A.HumMol Genet. 2000;9(14):2141-2147.
9. Bushby KM, Beckmann JS. The limb-girdle
muscular dystrophies—proposal for a new
nomenclature.Neuromuscul Disord. 1995;5(4):
337-343.
10. Nigro V, Savarese M. Genetic basis of
limb-girdle muscular dystrophies: the 2014 update.
Acta Myol. 2014;33(1):1-12.
11. Narayanaswami P, Weiss M, Selcen D, et al;
Guideline Development Subcommittee of the
American Academy of Neurology; Practice Issues
Review Panel of the American Association of
Neuromuscular & Electrodiagnostic Medicine.
Evidence-based guideline summary: diagnosis and
treatment of limb-girdle and distal dystrophies:
report of the guideline development subcommittee
of the American Academy of Neurology and the
practice issues review panel of the American
Association of Neuromuscular & Electrodiagnostic
Medicine.Neurology. 2014;83(16):1453-1463.
12. KeoghMJ, Chinnery PF. Next generation
sequencing for neurological diseases: new hope or
new hype? Clin Neurol Neurosurg. 2013;115(7):
948-953.
13. Rabbani B, Mahdieh N, Hosomichi K, Nakaoka
H, Inoue I. Next-generation sequencing: impact of
exome sequencing in characterizing Mendelian
disorders. J Hum Genet. 2012;57(10):621-632.
14. Sanger F, Nicklen S, Coulson AR. DNA
sequencing with chain-terminating inhibitors. Proc
Natl Acad Sci U S A. 1977;74(12):5463-5467.
15. McPherson JD, Marra M, Hillier L, et al;
International Human GenomeMapping
Consortium. A physical map of the human genome.
Nature. 2001;409(6822):934-941.
16. Majewski J, Schwartzentruber J, Lalonde E,
Montpetit A, Jabado N.What can exome
sequencing do for you? J Med Genet. 2011;48(9):
580-589.
17. BamshadMJ, Ng SB, Bigham AW, et al. Exome
sequencing as a tool for Mendelian disease gene
discovery.Nat Rev Genet. 2011;12(11):745-755.
18. Ghaoui R, Cooper ST, Lek M, et al. Use of
whole-exome sequencing for diagnosis of
limb-girdle muscular dystrophy: outcomes and
lessons learned [published online October 5, 2015].
JAMA Neurol. doi:10.1001/jamaneurol.2015.2274.
19. Committee on a Framework for Development
a New Taxonomy of Disease; Board of Life
Sciences; Division on Earth and Life Studies;
National Research Council. Toward Precision
Medicine: Building a Knowledge Network for
Biomedical Research and a New Taxonomy of
Disease.Washington, DC: National Academies
Press; 2011.
Equivalence of Glatiramer Acetate GenericsWith Branded
Glatiramer Acetate in Efficacy and Cost for the Treatment
ofMultiple Sclerosis
Dennis Bourdette, MD; Daniel Hartung, PharmD, MPH
Between 1993 and 2015, the US Food and Drug Administra-
tion (FDA) approved 13 drugs for the treatment of relapsing-
remitting multiple sclerosis (MS). While these disease-
modifying therapies (DMTs) fall into 7different categories and
vary in route of administra-
tion, adverse effects, and ef-
ficacy, they have one com-
monality—they are all very
expensive,withacquisitioncostsexceeding$60 000ayearand
continuing to escalate.1 One potential reason for the skyrock-
etingcostsofMSDMTs is that theyhavenever facedprice com-
petition from lower-cost generic drugs. The recent FDA ap-
proval of a generic version of branded glatiramer acetate
(Copaxone; TevaPharmaceuticals) signals thepromiseof true
price competition among MS DMTs. However, the economic
effect of the availability of a generic DMT is as yet unclear be-
cause this depends on the price of the generic and the extent
of its use. Although pricing decisions are beyond our control,
neurologists can have a large influence on how generic DMTs
are used. As such, neurologists need to assess whether or not
generic glatiramer acetate is equivalent to branded glati-
ramer acetate and acceptable for use in treating MS.
Glatiramer acetate emerged from research started in the
1960s at the Weizmann Institute of Science. Arnon and
colleagues2,3 assessed theeffects of synthetic polypeptideson
theMSmodel of experimental autoimmune encephalomyeli-
tis. The glatiramer acetate products contain polypeptides
formed from the random polymerization of L-alanine,
L-lysine,L-glutamicacid, andL-tyrosine inamolar ratioof6.0:
4.7:1.9:1. Glatiramer acetate contains polypeptides of varying
lengths that fallwithinadefinedmolecularweight range (4.7-10
kDa). Therefore, it is a complex drug and not a simple small-
molecule drug. The first successful double-blind placebo-
controlled trial of glatiramer acetate in relapsing-remittingMS
used the drug made in small batches at the Weizmann Insti-
tuteofScience.2,4Thedevelopmentof themanufacturing tech-
niques and quality controls needed to produce a commercial
product tookTevaPharmaceuticals about 2 years andwasnot
a trivial process.2 Itwas this version of glatiramer acetate that
was studied in the pivotal phase 3 trial and eventually be-
came commercially available.5
In 1995, theFDAapprovedbrandedglatiramer acetate, in-
jected subcutaneously in a dose of 20 mg/d, and it is now
widely prescribed.Glatiramer acetate has anoutstanding rec-
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